EUCTR2007-002969-12-DE进行中（未招募）不适用
A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER
Pfizer Inc. - 235 East 42nd Street - New York - 100170 个研究点目标入组 740 人开始时间: 2007年8月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 740
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histologically or cytologically proven diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease. Locally recurrent disease must not be amenable to resection OR radiation therapy with curative intent.
- •2.Measurable disease as per RECIST or bone-only disease. (Enrollment of patients having bone-only disease is at the discretion of Principal Investigators and Institutional Review Boards/Ethics Committees at participating institutions. Patients having bone-only disease will be required to undergo an additional bone scan at week 8 of the study. Patients having bone-only disease that are hormone receptor-positive must have progressed on previous hormone therapy)
- •3.Male or female, 18 years of age or older.
- •4.ECOG performance status 0 or 1.
- •5.Resolution of all acute toxic effects of prior therapy or surgical procedures to grade =1 (except alopecia) or other not toxicities considered a safety risk for the patient.
- •6.Adequate organ function as defined by the following criteria:
- •Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =2.5 x upper limit of normal (ULN), or AST and ALT =5 x ULN if liver function abnormalities are due to underlying malignancy
- •Total serum bilirubin =1.5 x ULN (Patients with Gilbert’s disease may not be required to meet this criterion.)
- •Serum albumin >=2.5 g/dL
- •Absolute neutrophil count (ANC) >=1500/µL
- •Platelets >=100,000/µL
- •Hemoglobin >=8.5 g/dL
- •Serum creatinine =1.5 x ULN
- •Urine protein:creatinine ratio <1
- •Left ventricular ejection fraction (LVEF) equal to or above 50% as measured by either multigated acquisition (MUGA) scan or echocardiogram (ECHO).
- •7.Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
- •8.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. HER2/neu positive disease unless trastuzumab was previously received and the patient experience progression or trastuzumab was contraindicated.
- •2. Receipt of a taxane in the adjuvant setting unless disease free interval =12 months after end of treatment.
- •3. Prior treatment with bevacizumab or SU011248.
- •4. Prior treatment with cytotoxic anti-cancer therapies in the advanced disease setting. (Hormonal therapy for advanced disease is allowed, but must be discontinued prior to the start of study treatment).
- •5. History of dose-limiting hypersensitivity reactions to paclitaxel, Cremophor EL, Chinese hamster ovary cell product or other recombinant human antibodies.
- •6. Radiation therapy within 2 weeks of first study treatment.
- •7. Major surgery within 4 weeks of first study treatment. At least 7 days should elapse from the time of minor surgical procedure including placement of an access device.
- •8. Wounds that have not completely healed, active ulcer(s), or bone fracture(s).
- •9. Deleted in Amendment #2 (prior high-dose chemotherapy).
- •10. Deleted in Amendment #2 (prior radiation therapy to >25% of the bone marrow).
- •11. Current treatment on another clinical trial.
- •12. Presence of brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.
- •13. Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- •14. Any of the following within the 6 months prior to starting study treatment: myocardial infarction, severe/unstable angina, congestive heart failure, cerebrovascular accident including transient ischemic attack, pulmonary embolus, deep vein thrombosis or other significant thromboembolic events.
- •15. Ongoing cardiac dysrhythmias of NCI CTCAE grade =2 or QTc interval >450 msec for males or >470 msec for females.
- •16. Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- •17. Current treatment with therapeutic doses of coumarin-derivatives such as warfarin and phenprocoumon (use of low dose for deep vein thrombosis prophylaxis is allowed) or oral anti-vitamin K agents. If currently receiving treatment with oral coumarin-derivatives, patients must have their PT measured and their INR monitored.
- •Patients with an INR >1.5 will be excluded from enrollment. Low molecular weight heparin is allowed at any dose level.
- •18. History of gross hemorrhage within the past 6 months (eg, hemoptysis or hematuria requiring medical intervention).
- •19. Known human immunodeficiency virus infection.
- •20. Female who is pregnant or nursing; female of child-bearing potential who is unwilling or unable to use adequate contraception to prevent pregnancy during the trial and for 90 days after the last dose of study treatment. All female patients with reproductive potential must have a negative pregnancy test (serum or urine)
- •prior to randomization.
- •21. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
不适用
A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER - NDocally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2007-002969-12-ITPFIZER740
进行中（未招募）
不适用
Estudio en fase 3 de SU011248 en combinación con paclitaxel versus bevacizumab con paclitaxel como tratamiento de primera linea en pacientes con cáncer de mama avanzado. A phase 3 study of SU011248 in combination with paclitaxel versus bevacizumab with paclitaxel in the first-line advanced disease setting in patients having breast cancer.Cáncer de mama localmente recurrente o metastásicoLocally recurrent or metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10006198Term: Breast cancer recurrentMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-002969-12-ESPfizer, S.A.740
进行中（未招募）
1 期
Etude de phase III du SU011248 chez les patients atteints d'un cancer épidermoïde de la tête et du cou en situation de rechute locorégionale et/ou métastatiqueCet essai s'adresse à des patients porteurs d'un carcinome épidermoïde de la tête et du cou en rechute locale ou en situation métastatique et qui ne peuvent plus bénéficier d'un traitement curatifMedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-001780-30-FRCL Saint Luc 1200 Bruxelles37
进行中（未招募）
不适用
A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma.EUCTR2004-001149-14-ITPFIZER
进行中（未招募）
1 期
A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell CarcinomaMedDRA version: 9.1 Level: HLT Classification code 10038408 Term: Renal cell carcinomasRenal Cell CarcinomaEUCTR2004-001149-14-GBPfizer Inc. - 235 East 42nd Street - New York - 10017690